NEW YORK-More than 500 cancer patients across the country participated in a Cancer Care, Inc. teleconference addressing a little-discussed concern literally on the mind of many chemotherapy patients: forgetfulness during and after chemotherapy.
NEW YORKMore than 500 cancer patients across the country participated in a Cancer Care, Inc. teleconference addressing a little-discussed concern literally on the mind of many chemotherapy patients: forgetfulness during and after chemotherapy.
Cancer patients sometime refer to the condition jokingly as "chemo-brain" or "chemo-head," but it can be frightening if not understood, said Stewart Fleishman, MD, director of cancer supportive services, Beth Israel Cancer Center, New York.
Many worry about Alzheimer’s disease, he said, and need to be reassured that the sudden appearance of memory gaps during treatment is not a sign of dementia. Alzheimer’s is slow to develop, not sudden, he stressed.
Although mental fatigue is often associated with breast cancer treatment, it also occurs in men receiving chemotherapy, Dr. Fleishman said. "Female patients are much more likely to speak up about this. Men don’t want to admit they are not up to their usual level of activity or function," he said. He noted that men undergoing prostate cancer treatment often have similar problems in remembering where they put their keys and getting lost when driving.
People become tired and forgetful during chemotherapy because most of the drugs are designed to seep into the brain, Dr. Fleishman explained. Because these drugs are potent, patients also receive therapies that act on the brain to control nausea, vomiting, and dizziness.
A patient who is concerned about mental changes should discuss the problem with an oncologist or oncology nurse, he advised. The practitioner can make sure the patient is not anemic, developing an infection, or severely depressed. These can be treated, but some fatigue, mentally as well as physically, is to be expected, Dr. Fleishman said.
He offered several practical suggestions for coping with mental fatigue.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.